Le Lézard
Classified in: Health
Subject: FDA

Scottsdale's Aesthetic IQ Clinic Offers Breakthrough Undereye Treatment, Restylane® Eyelight


The newest hyaluronic acid filler by Galderma is now FDA-approved

SCOTTSDALE, Ariz., Sept. 13, 2023 /PRNewswire-PRWeb/ -- Aesthetic IQ Clinic now offers Galderma's newest hyaluronic acid filler that was recently approved by the U.S. Food and Drug Administration (FDA) called Restylane® Eyelight. The undereye hyaluronic acid (HA) dermal filler, is the first and only product in the U.S. formulated with NASHA® Technology for volume loss, giving patients natural-looking results to treat undereye hallows, also known as shadows in adults over the age of 21.

"This exciting new treatment is formulated with NASHA Technology which means the filler is close to the body's natural hyaluronic acid," said Marissa Abdo, MS, RN, CANS, owner of Scottsdale-based Aesthetic IQ Clinic.

"This exciting new treatment is formulated with NASHA Technology which means the filler is close to the body's natural hyaluronic acid and produces a firm supportive gel that is resistant to water absorption which makes Restylane Eyelight an excellent solution for patients who suffer from undereye volume loss," said Marissa Abdo, MS, RN, CANS, owner of Scottsdale-based Aesthetic IQ Clinic.

For millions of Americans, dark circles can make them feel older, tired and stressed. Lack of volume and volume loss in the undereye region can create shadows and emphasize dark circles, leading to the appearance of tiredness and aging. In a study, 87% of patients had reduced undereye hollowness at 3 months and Restylane Eyelight was found to be well tolerated under the eyes. At 3 months, 92% of patients were pleased with their results, and 84% were still pleased through 1 year. The study also yielded high satisfaction, with 93% of patients expressing interest in receiving treatment again after 12 months.

"The results also showed that most patients - around 87% - did not experience adverse events related to treatment with Restylane Eyelight, giving them a new treatment option that is safe and effective for this very common problem," said Abdo. "The most observed side effects for undereye injections are swelling, redness, tenderness, pain, bruising, itching, and lumps or bumps at the injection site."

The FDA approval of Restylane Eyelight adds to Galderma's growing Restylane product portfolio. With over 65 million treatments worldwide and counting, the Restylane family of HA dermal fillers is the broadest portfolio of dermal fillers in the U.S. For more information about this treatment, call 480.454.5577, visit AestheticIQClinic.com or schedule an appointment at the office. Aesthetic IQ Clinic is located at 7054 E Cochise Rd. B200 Scottsdale, AZ 85253. You can follow the clinic on social media @Marissa.AestheticIQ.

About Marissa Abdo
Aesthetic IQ's founder, Marissa Abdo, MS, RN, CANS, was formerly on the staff of Beverly Hills' Dr. 90210 and is a preferred injector for Hollywood's elite and celebrities. At this unique aesthetic clinic, Abdo focuses on her clients' facial anatomy to improve their overall beauty. She is a firm believer in empowering women both through her professional services and through education. As a top national trainer for Galderma and Allergen, Abdo has trained healthcare professionals at more than 100 locations in the Scottsdale area. She is dedicated to creating an empowered community of practitioners who can safely administer injections to all patients and believes that every injector should have a seat at the table. In terms of service and outcomes, Abdo is leading the way and establishing the bar for the injection industry. Through Aesthetic IQ, she is pleased to provide each patient?from mature patients to children and even men?with a personalized experience. Each patient receives assistance from Abdo in realizing their beauty and their unique contribution to the world.

Media Contact

Holly Morgan, Holly Morgan Media, 1 4808886074, [email protected], hollymorganmedia.com

SOURCE Aesthetic IQ Clinic


These press releases may also interest you

at 00:05
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

30 avr 2024
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of...

30 avr 2024
Waverley Pharma Inc. ("Waverley Pharma" or the "Company") , a Canadian pharmaceutical company, is announcing a business update. As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing...

30 avr 2024
Feeding Matters is proud to celebrate the 6th annual PFD Awareness Month, which is recognized around the globe. This designation, initiated by Feeding...

30 avr 2024
Korea Ginseng Corp. US (KGCUS) aka JungKwanJang held a dedicated international seminar session on "Korean Ginseng: Safety, Efficacy And Neuroprotective Insights'' at the International Conference on the Science of Botanicals (ICSB) hosted by the...



News published on and distributed by: